West HJ, Mccleland M, Cappuzzo F et al (2022) Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial. The gene discussed is TP53; the disease is non-small cell lung carcinoma.